Anne (2) - England: Multiple Sclerosis (MS) (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Linda Elsegood: like to introduce Anne from England who takes LDN for multiple sclerosis. Good morning 

Anne (England): Good morning. 

Alan - England: Multiple Sclerosis; MS (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Linda: I would like to introduce Alan from England. Alan has multiple sclerosis.

Alan: Hello. Could you tell us when you first started getting ms symptoms?

A Comparison of Medication-Assisted Treatment Options for Opioid Addiction: A Review of the Literature

J Addict Nurs
30 June 2021
https://pubmed.ncbi.nlm.nih.gov/34224485/

Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice

Pharmacol Biochem Behav
02 July 2021
https://pubmed.ncbi.nlm.nih.gov/34224734/

Psychopharmacologic Therapies for Irritable Bowel Syndrome (Abstract)

Gastroenterol Clin North Am
Epub 01 July 2021
https://pubmed.ncbi.nlm.nih.gov/34304793/

Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and β-Endorphin

eNeuro
126 June 2021
https://pubmed.ncbi.nlm.nih.gov/34031099/

Integrated Review of the Assessment of Newborns With Neonatal Abstinence Syndrome

J Obstet Gynecol Neonatal Nurs
08 June 2021
https://pubmed.ncbi.nlm.nih.gov/34116058/

Objective: To critically review and summarize current knowledge regarding the assessment of newborns with neonatal abstinence syndrome (NAS).

Extended-release naltrexone for youth with opioid use disorder

J Subst Abuse Treat
15 April 2021
https://pubmed.ncbi.nlm.nih.gov/34118699/

Background: Few published research studies have examined the effectiveness of extended-release naltrexone (XR-NTX) for the treatment of opioid use disorder (OUD) among adolescents and young adults.

Complex Regional Pain Syndrome: A Comprehensive Review 

Pain Ther
24 June 2021
https://pubmed.ncbi.nlm.nih.gov/34165690/

Campbell Neurosciences Spin Off of Therapeutic Solutions Reports Synergistic Reduction of Schizophrenia in Animal Models using Low Dose Naltrexone and T Regulatory Cell Stimulation